The wind of change in the management of autosomal dominant polycystic kidney disease in childhood

Charlotte Gimpel1,2 • Carsten Bergmann1,3 • Djalila Mekahli4,5

Received: 26 November 2020 / Revised: 28 December 2020 / Accepted: 27 January 2021 / Published online: 7 March 2021
© The Author(s) 2021, corrected publication 2021

Abstract
Significant progress has been made in understanding the genetic basis of autosomal dominant polycystic kidney disease (ADPKD), quantifying disease manifestations in children, exploring very-early onset ADPKD as well as pharmacological delay of disease progression in adults. At least 20% of children with ADPKD have relevant, yet mainly asymptomatic disease manifestations such as hypertension or proteinuria (in line with findings in adults with ADPKD, where hypertension and cardiovascular damage precede decline in kidney function). We propose an algorithm for work-up and management based on current recommendations that integrates the need to screen regularly for hypertension and proteinuria in offspring of affected parents with different options regarding diagnostic testing, which need to be discussed with the family with regard to ethical and practical aspects. Indications and scope of genetic testing are discussed. Pharmacological management includes renin-angiotensin system blockade as first-line therapy for hypertension and proteinuria. The vasopressin receptor antagonist tolvaptan is licensed for delaying disease progression in adults with ADPKD who are likely to experience kidney failure. A clinical trial in children is currently ongoing; however, valid prediction models to identify children likely to suffer kidney failure are lacking. Non-pharmacological interventions in this population also deserve further study.

Keywords Autosomal dominant polycystic kidney disease (ADPKD) • Children • Adolescent • Neonate • Hypertension • Proteinuria • Tolvaptan

Introduction
Gone are the days when autosomal dominant polycystic kidney disease (ADPKD) was known as “adult” rather than “autosomal dominant” polycystic kidney disease and research into many aspects of ADPKD has been very dynamic in recent years. However, because kidney failure does not occur until a median age of 55–75 years [1], clinical manifestations in children and young adults still tend to be underestimated in our experience, especially by family physicians and adult nephrologists. Combined with legitimate worries about testing for an asymptomatic disease in children, this can lead to unwarranted neglect of treatable disease manifestations in young people which jeopardizes their future kidney function. On the other hand, awareness and understanding of very-early onset (VEO) and severe forms of ADPKD have increased in the last years and enhanced our knowledge of the prevalence and genetic basis of severe childhood ADPKD. Simultaneously, the use of newly approved tolvaptan (and other disease-modifying drugs that are currently being evaluated in clinical trials) is restricted to adults with radiological criteria of rapid disease
progression, which often means waiting until the kidney has already been irreversibly damaged by progressive cyst growth. Therefore, the pediatric early stages of ADPKD represent a novel and crucial target for disease understanding and treatment. Here we aim to review the spectrum of clinical manifestations of ADPKD in children, the possibilities and dilemmas of different diagnostic methods and management options in order to give an update on recent developments in this dynamic field.

**Clinical manifestation of ADPKD in childhood**

**Classical ADPKD**

The symptomatic manifestations of ADPKD in childhood remain difficult to grasp. Even though the prevalence of abdominal, flank, or back pain is reported between 16 and 30% [2–4], this occurs with a similar prevalence in the general pediatric population [5], and unfortunately no direct comparative studies exist. The same is true for nocturnal enuresis and urinary frequency which may be symptoms of low urinary concentrating ability [6], as well as for urinary tract infections [2–4, 7, 8]. A history of hematuria, which can be considered a more specific symptom, is reported in about 10% of pediatric case series [2, 3, 7–10]. This is consistent with investigations in adults, where 10% report a first episode of gross hematuria before the age of 16 [11].

However, asymptomatic disease manifestations are prevalent. A recent meta-analysis by Marlais et al. revealed that 20% of children with ADPKD had hypertension in 14 studies including over 900 patients (95% confidence interval: 15–27%) [12]. The incidence of hypertension increased with age in meta-regression. This fits with the increasing prevalence of hypertension reported throughout adult life in patients with ADPKD and the fact that hypertension and hypertensive vascular damage often precedes kidney damage in ADPKD [13]. Still, results are sometimes questioned because many studies of children with ADPKD are performed in tertiary centers and may have a referral bias towards more severe cases. However, the meta-analysis reports a similar rate of hypertension when removing the three studies with the highest likelihood of selection bias. Also, a direct comparative study of children diagnosed with ADPKD due to symptoms or screening, did not identify relevant differences in disease severity [3] and adult studies which included patients in their twenties show similar proportions of hypertension [14]. In addition, a 24-h blood pressure study in children with ADPKD revealed a high proportion of isolated nocturnal hypertension [15]; thus, clinic blood pressure measurements alone may even underestimate the true incidence of hypertension. Hypertensive children with ADPKD probably experience faster prospective decline of kidney function and kidney growth than their normotensive peers [16].

Hypertension in children with ADPKD is accompanied by measurable cardiovascular damage [17–19] and even those with blood pressure at the higher end of normal (75th to 95th percentile) already have increased left ventricular mass index compared to normotensive peers [17]. This is compatible with the finding that adults with ADPKD also suffer considerable cardiovascular damage prior to decline of kidney function which probably relates to activation of the renin-angiotensin system by ischemic cyst compression and loss of PKD1/2-dependent production of nitric oxide by vascular smooth muscle cells [13, 20, 21].

With regard to proteinuria, this was found in 20% (95% confidence interval: 9–40%) of 508 children in 8 studies [12]. As in adults [22], proteinuria is usually very mild or mild. The prevalence of hypertension and proteinuria appear not to correlate with each other both in the meta-analysis and within individual studies [12, 23, 24].

Reduced kidney function is not a main feature of childhood ADPKD; however, the mean risk of reduced GFR in meta-analysis is 8%, but varies widely between different pediatric case series (95% CI: 2–26%, range 2–39%) [2, 12]. Glomerular hyperfiltration, which may herald loss of GFR, can be observed in about 20% of children with ADPKD [4, 25, 26], but there is no uniform definition of this phenomenon. In a prospective pediatric study, glomerular hyperfiltration was associated with faster increase in kidney volume, as well as faster decline of GFR during follow-up [4]. This is probably the main reason why cross-sectional pediatric studies usually show no correlation between kidney volume and GFR [23], despite the fact that this is well established in adults [27].

**Extrarenal disease manifestations and distinguishing phenotypes**

Hepatic cysts are only a minor concern in children with ADPKD, as single cysts are reported in only 0–4% with no cases of significant liver disease [2–4, 7–9, 23]. The same holds true for ductal plate malformation (i.e. congenital hepatic fibrosis and hyperplastic biliary ducts) which has only been described in a few anecdotal cases of ADPKD, but which is a constant feature in ARPKD and frequently observed in many other syndromic ciliopathies [28]. The incidence of cerebral aneurysms is also negligible in children, with only rare case reports. A high incidence of mitral valve prolapse (12%) in an older study [29] could not be confirmed subsequently [8]. The incidence of inguinal hernias appears quite high with around 10% in only two studies reporting on this outcome [2, 9], and was significantly higher in the group of children presenting with ADPKD £ 0 [9].

Mutations in a large number of other genes can also mimic ADPKD and need to be taken into consideration for
differential diagnosis, especially for children with negative family history (for details see [30]). For example, mutations in HNF1B (also known as TCF2) can mimic ADPKD and ADPKDVEO, as HNF1B is involved in regulating PKD2 expression as a transcription factor [31, 32]. However, neither hypomagnesaemia nor elevated liver enzymes are features of ADPKD, which may be a helpful diagnostic clue when considering HNF1B-mutation as a differential diagnosis [33]. Patients with Bardet-Biedl syndrome may also present with ADPKD-like kidney cysts, which may be caused by the involvement of BBS1 and 3 in ciliary trafficking of polycystin 1 (the PKD1 gene product) [34]. Again, extrarenal signs such as polyactyly, obesity, or retinal disease may give helpful clues here.

**VEO, prenatal, and severe ADPKD**

It has been recognized for some time that a subgroup of children have more severe ADPKD than the classical course and may even suffer kidney failure (i.e. stage 5 chronic kidney disease (CKD)) at an early age [2]. These children tend to present earlier in life with symptomatic disease that can even resemble the much more severe autosomal recessive polycystic kidney disease (ARPKD) with oligohydramnios, pulmonary hypoplasia, and consequently severe respiratory distress after birth [7, 35, 36].

Children with ADPKDVEO have a higher risk of early loss of kidney function. A well-matched case-control study found that 50% of ADPKDVEO children and 30% of non-VEO children progressed to eGFR < 90 ml/min/1.73 m² during a long follow-up period and that this occurred at a median age of 22 vs. 25 years (p < 0.05) [26]. All cases of early kidney failure occurred in the VEO group. Glomerular hyperfiltration was not more common, but occurred slightly earlier in the VEO group [26]. This group also had more hypertension and very enlarged kidneys [26].

This case-control study defined VEO as diagnosis before the age of 18 months, with most patients being diagnosed in the 1990s. However, especially as pre- and postnatal ultrasound has become much more sensitive, the sole detection of hyperechogenic normal-sized kidneys in an at-risk fetus should probably not be equated to VEO disease anymore. Even though it is likely to be due to the transmission of ADPKD, it does not necessarily implicate severe disease (own data, paper in preparation). Even prenatally enlarged kidneys are often no longer enlarged in childhood [7]. The Mayo Clinic group suggests to use the term ADPKDVEO when the diagnosis is made in utero with enlarged hyperechoic kidneys and/or oligohydramnios or before the age of 18 months with enlarged kidneys and one of the following: hypertension, persistent proteinuria or reduced GFR [37]. However, so far, evidence that isolated prenatally enlarged kidneys are really a risk factor for faster disease progression is lacking and it remains unclear whether some children without early onset still show rapid progression.

Genetic research has been helpful in understanding some of the large clinical variability of ADPKD. Already 25 years ago, children with the PKD1/TSC2 contiguous gene deletion syndrome, were discovered to present with early severe ADPKD together with tuberous sclerosis complex [38]. However, this is rare as the large deletion usually occurs de novo. While homozygous PKD1 mutations appear to be incompatible with life [39], biallelic hypomorphic PKD1 mutations can cause severe ARPKD-like forms [40, 41], and the combination of a classical and an ultra-low penetrant PKD1 mutation can also cause severe, early ADPKD [42]. Patients with early ADPKD are more likely to have such biallelic transmission than those with classical ADPKD [36, 41]. Digenic disease with variants in PKD1 and the newly identified ADPKD gene GANAB has also recently been identified in a child with early ADPKD [43]. Severe ADPKD may also be caused by combined transmission of mutations in PKD1 or 2 and other cystic kidney disease genes such as HNF1B or PKHD1 [42], but it is unclear to what proportion of ADPKDVEO children this applies.

**Understanding and stratifying disease variability**

Within the group of patients with classical ADPKD, there is also considerable variability in age of onset and progression of kidney disease. Trying to identify patients at higher risk of severe disease is not only of academic interest. As some adults with ADPKD never reach kidney failure (stage 5 CKD) within a normal life span, patients who would benefit from treatments to delay disease progression need to be identified in order to save others from the unnecessary effort, risk, and cost of such treatments.

Genetic studies have been able to identify more rapid kidney growth and loss of kidney function both in adults and children with PKD1 as opposed to PKD2 mutations [8, 44], which are causative in approximately 80 and 15% of adult cases respectively. Consequently, truncating PKD1 mutations were shown to cause more rapid progression than non-truncating ones [45]. Within the last 5 years, various other genes could be identified in the small percentage of patients without PKD1 or 2 mutations: mutations in GANAB cause generally mild cases of ADPKD and polycystic liver disease [46], patients with DNAJB11 variants have non-enlarged or atrophic kidneys with interstitial fibrosis [47] and mutations in ALG9 also cause polycystic kidney and/or liver disease [48], but the further characterization of disease progression in the latter two is still lacking.

In terms of clinical markers, extensive radiological studies in adults have identified total kidney volume adjusted to height (htTKV) as good a good predictor of disease
progression, which is easy to apply with the Mayo imaging classification [49], but only applicable from 16 years of age and in patients without unusual kidney shapes.

Consequently, both genotype (truncating vs. non-truncating PKD1, PKD1 vs. PKD2) and total kidney volume have been integrated into scoring systems to predict the individual likelihood of reaching kidney failure (e.g., PROPKD Score) together with clinical risk factors such as gender and hypertension or urological events before the age of 35 years [50].

Additionally, several biomarkers have been found to correlate with disease severity and progression in adults, such as plasma copeptin (a surrogate for endogenous vasopressin levels) [51], urinary MCP-1 (a chemotactic factor for circulating monocytes and a pro-inflammatory activator of macrophages) [52–54]. Urinary EGF (a marker of functional tubular cell mass and of progression in both adults and children with CKD [55]) may also be useful in ADPKD [56], but all these biomarkers have not been studied in early ADPKD.

The lack of early prognostic markers to inform long-term decision making in adults remains a dilemma for both physicians and patients [57]. In children, such knowledge is even more limited and much longer-term studies are needed to achieve the same goal.

**Establishing the diagnosis**

**Asymptomatic at-risk children**

For minors without symptoms of ADPKD who are known to be at-risk because of an affected parent, the first important management step is an in-depth discussion about the approach to diagnostic testing (see Fig. 1). While genetic testing of asymptomatic minors for untreatable adult-onset diseases is generally considered unethical [59], it is deemed permissible by both the American and European Societies of Human Genetics if treatment is available during childhood [60, 61]. Unfortunately, ADPKD does not fit neatly into such categories because children frequently have signs such as hypertension and proteinuria even without subjective symptoms, and the treatments of hypertension and proteinuria are effective, low-risk, and have proven long-term benefit, but are not strictly speaking curative. Also, it is possible to screen for hypertension and proteinuria without uncovering transmission status to children who have neither signs nor symptoms of ADPKD. However, some parents or young people may still feel a considerable psychological burden of uncertainty about transmission status and/or the need for repetitive examinations despite a 50% chance of being unaffected. Because childhood ADPKD is incurable but not untreated, diagnostic testing can be considered, but should involve thorough prior counselling of both parents and mature children, who should be aware of all three possible management pathways illustrated in Fig. 1. Parents and the minor should understand the legal consequences that apply in their country regarding future securement of insurance policies and jobs, if a diagnosis is made in an asymptomatic person. In Germany and Belgium for example, but also in many other countries, results of pre-symptomatic genetic testing may be legally withheld from insurance companies [59], while there is no such legislation for radiological findings. The US also has a federal law which permits withholding results of presymptomatic genetic tests from health insurance companies and employers, but not from life or long-term care insurance [62], with additional heterogeneous regulations in individual states. In other countries, there may be no statutory protection, such as in the UK, where a voluntary code of conduct needs regular renewal [63]. Close interdisciplinary collaboration with a clinical geneticist is therefore helpful to inform and counsel families in navigating this challenging decision.

If diagnostic testing is agreed upon, ultrasound is a non-invasive, easy to perform and specific diagnostic tool. Even though the radiological definition of ADPKD in adults and adolescents over 16 years requires ≥ 3 cysts, in at-risk children with a positive family history even 1 cyst can be considered very likely evidence of ADPKD, as simple cysts are very rare in children and follow-up is highly likely to confirm cystic disease [64, 65]. However, especially in younger children, the absence of cysts on ultrasound is insufficient to exclude ADPKD [66] as even in adults this is not possible until the age of 40 years [65]. Genetic testing may be preferred because of higher sensitivity and legal implications in some countries. However, there is currently no added benefit of genetic testing in children with an established radiological diagnosis and classical presentation and family history, but this may change in future if disease-modifying treatment and prediction scores which include genetic subtypes are established in children. Children with a confirmed or equivocal diagnosis of ADPKD should be enrolled into regular screening for disease manifestations (see Fig. 1 and “Management” section), while only children with a negative genetic test may be safely discharged into routine pediatric care.

**Incidental cysts, symptomatic, and severe disease**

For children with the incidental finding of kidney cysts on ultrasound (usually on investigation of symptoms such as abdominal pain, enuresis, urinary tract infection or hematuria), the question of family history should be addressed first (see top right-hand side of Fig. 1). This may require ultrasound examination of the parents (and grandparents if the parents are under 40 years old). A similar approach should be taken if there is prenatal suspicion of ADPKD, which is more likely to manifest with enlarged hyperchogenic fetal kidneys than visible cysts. In both scenarios, a negative family history should prompt further work-up of the presenting symptoms as well as investigations for other kidney diseases.
From the discussion on severe and early ADPKD above, it is evident that in children with severe ADPKD VEO genetic analysis is usually advisable [58], as knowledge of the exact genotype helps to counsel on recurrence risk within the family and may improve the prediction of the clinical course.

Preimplantation genetic diagnosis (PGD)

Even though this is not strictly a pediatric issue, pediatricians should be aware that PGD for ADPKD is possible if genetic studies in the affected parent are completed and conclusive before conception. Several recent publications report on PGD for ADPKD with a cumulative success rate per couple of 58–65% [67–69]. In addition to ethical issues surrounding the procedure itself, ADPKD may be deemed a questionable indication because it is a severe, but not necessarily life-threatening or even life-limiting disease and a first disease-modifying treatment is available. On the other hand, it can be deemed especially suitable, because of the higher transmission risk than in recessive diseases and the high likelihood of identifying a causative mutation in the affected parent. In view of the wide range of attitudes towards PGD among patients affected with ADPKD and their doctors [70, 71], prospective parents deserve to be informed in order to take an independent decision [72], which will also depend on their local regulatory framework and financial coverage [73].

Management

As illustrated in the bottom half of Fig. 1, very similar monitoring and counselling guidelines apply for at-risk children with an unknown, equivocal or confirmed diagnosis of ADPKD. Good long-term care often still requires overcoming a mindset of ADPKD as an adult disease and should be viewed as repeated opportunities for screening and counselling, two pediatric key areas of expertise.
Monitoring and counselling

Based on the relatively high incidence of hypertension and proteinuria detailed above, two recent clinical guidelines recommend to examine urine and blood pressure in all at-risk children at regular intervals [58, 74]. Because of generally slow disease progression, large intervals of one to several years are usually sufficient and should not be overly burdensome for those children who turn out not to be affected. For school-aged children, it is worth investing the extra effort of 24-h ambulatory rather than just clinic blood pressure measurements, due to the high incidence of isolated nighttime hypertension [15], and to take the time to educate about lifestyle factors which influence blood pressure and progression of ADPKD (see Fig. 1 and section on “Non-pharmacological management”).

Even in children with an established diagnosis of ADPKD, repeated ultrasound examinations and “cyst counting” are of limited value for clinical management yet may cause significant anxiety for patients and families. Although the number of cysts and kidney volume have some correlation with hypertension, ultrasound does not replace blood pressure measurements. However, ultrasound examinations are useful in the work-up of clinical events such as urinary tract infections, hematuria, or abdominal pain. There is no need to screen children or adolescents for cerebral aneurysms or hepatic involvement, due to the extremely low incidence in young people with ADPKD.

Testing for hypertension and proteinuria can be done without revealing transmission status in children who have neither signs nor symptoms of ADPKD while children with positive findings can undergo focused work-up. It also provides repeated opportunities for families to communicate with their children about the possibility of disease transmission. Many families find this challenging, e.g., because of parental feelings of guilt or helplessness and traumatic experiences with the disease in older relatives, and may benefit from external help [75, 76]. Initiating age-appropriate communication about the risk of disease early on helps to improve family communication and improves long-term coping strategies [77, 78]. If the parents have chosen not to communicate the risk of disease transmission with their offspring during childhood, they should still be encouraged to address this issue when their children reach the age of maturity, as the ability to choose presymptomatic testing is perceived by many patients as an important and valuable opportunity to take ownership of their health [79].

Antihypertensive and antiproteinuric treatment

Antihypertensive and antiproteinuric treatment have the dual aims of lowering cardiovascular mortality and preserving kidney function, because blood pressure is one of the important modifiable risk factors. There are universal recommendations to lower blood pressure in children with hypertension and especially children with CKD [80–83] with a host of evidence, but we will focus on reviewing ADPKD-specific evidence here.

Adults with CKD already have a large increase in cardiovascular mortality, however, patients with ADPKD are at an even higher risk of cardiovascular disease than matched patients with other causes of CKD [84, 85]. This may be due to intrarenal activation of the renin-angiotensin system by local cystic destruction and a high incidence of hypertension [13, 20]. Placebo-controlled trials are not available for patients with ADPKD, but the decrease over time of the very high incidence of left ventricular hypertrophy in this group may be attributable to the more intensive treatment approaches to hypertension [86]. In the HALT-PKD A study, more intensive lowering of blood pressure (but not single vs. dual RAS blockade) resulted in a greater decline of left ventricular mass index in adults with early ADPKD [87]. This is in line with other studies which confirm a benefit of intensive blood pressure control on cardiovascular events, especially in high risk groups [88].

Generally, proteinuric patients appear to be at greater risk of complications of hypertension and accordingly benefit more from intensive blood pressure lowering [89], although due to the combined antihypertensive and antiproteinuric effect of RAS blockade this effect is difficult to separate in many clinical trials. In the HALT-PKD B trial an ACE inhibitor alone was not different to dual RAS blockade in preventing a composite outcome of death and loss of kidney function in later stages of ADPKD, with similar blood pressure levels achieved in both groups [90].

Intensive blood pressure lowering appears to have greater benefits on cardiovascular mortality than on protection of kidney function in adults [88], and this is also true for ADPKD, where intensive antihypertensive treatment reduced growth of kidney volume but not loss of GFR [87, 91, 92]. In children, strict blood pressure control could further slow the decline of GFR in a large cohort with mixed-origin CKD [93]. The only randomized controlled trial in children with ADPKD was much smaller and stratified into three groups of children with normal (< 75th percentile), high-normal (75th–95th percentile) and high blood pressure (> 95th percentile). Children starting from a high-normal blood pressure experienced a significant decrease in GFR and increase in serum creatinine and left ventricular mass index over 5 years, which did not occur in the group treated with ACE inhibitor [16]. Children with established hypertension all received ACE inhibition and did not experience a significant benefit from intensified versus conventional blood pressure control, but a high drop-out rate and difficulty to obtain target-blood pressure make analysis of this group difficult.
In terms of drug choice, RAS inhibition with ACE inhibitor or ARB blocker is generally preferred for adults with CKD due to the additional renoprotective effects in proteinuric patients [89]. For patients with ADPKD and hypertensive children, these drugs also have a much greater body of evidence, but direct evidence of their superiority over other antihypertensives is sparse [92]. However, diuretics should probably be avoided as they are associated with a larger loss of GFR in a small retrospective study [94]. Calcium channel blockers increase cyst growth in an animal model of ADPKD [95], but studies in humans have not shown a large effect [96–98]. In adults with ADPKD, there is no convincing benefit of double RAS control versus treatment with ACE inhibition or ARB blockade alone [87].

Pharmacological treatment to delay disease progression

This has been a very active area of research in the last decade. Many potential drugs have been identified from in vitro, animal and genetic studies, partly with extensive bioinformatic analysis [99], but we will focus here on those with pediatric data or which have been licensed in adults.

From a pediatric perspective, the fact that loss of GFR is a very gradual, continuous process, has both upsides and downsides: on the one hand, there is a theoretical benefit of starting to delay disease progression as early as possible in order to maximize the achieved delay of kidney failure [100]. Mathematical models of ADPKD progression support this idea; however, they necessarily extrapolate medium-term data to much longer time intervals [101]. On the other hand, starting pharmacological treatment early in life requires drugs with very good safety profiles. Additionally, there are several principal dilemmas for interventional pediatric ADPKD studies: firstly, GFR is not a good marker of progression in early disease (see ‘Complications of ADPKD’ above); however, even though kidney volume correlates well with kidney function and progression in adults [49], some drugs have had discrepant effects on the two and therefore kidney volume is not sufficient as a sole outcome measure [102]. Secondly, even a small reduction in the rate of disease progression would have a significant long-term effect but would require very large or very long-term studies, which are both difficult. Thirdly, in “real life” treatment of adolescents is often hampered with serious compliance problems and is more difficult in patients who feel subjectively well.

Nonetheless, in children with ADPKD who already received ACE inhibition, a prospective randomized controlled trial of pravastatin could show a significant reduction of height-adjusted kidney growth over 3 years [103]. There was also a non-significant reduction in left ventricular mass index, and kidney function was unchanged, as could be expected in a group with a mean creatinine clearance of 135 ml/min per 1.73 m² over this time span. Despite this promising effect, and a plausible mode of action via the anti-proliferative, anti-inflammatory and anti-oxidant effects of statins (HMG-CoA reductase inhibitors), which improve endothelial function and increase kidney blood flow, no larger confirmative studies have been initiated. This is probably due to lack of financial incentives and because the results are less relevant to the much larger adult ADPKD population, where statins are frequently used for their well-documented positive effect on the rate of death and cardiovascular events in CKD [104].

With regard to kidney function in adults with ADPKD, two small randomized trials of statins show conflicting results [105, 106] and a recent post hoc analysis of large adult treatment trials did not show positive effects of ongoing (non-standardized) statin treatments [107]. In terms of safety of statins in children, there were no safety concerns in the 3-year ADPKD study with around 50 children who received pravastatin, but longer-term safety data are only available from a variety of small studies in children with hyperlipidemia (e.g., [108]). At least recent post hoc analyses are reassuring about the safety of combined use of tolvaptan and statins in adults [109].

The vasopressin 2 receptor antagonist tolvaptan is thought to reduce cyst growth by blocking the effect of arginine vasopressin on collecting duct cells, which otherwise transmits proliferative stimuli via cyclic AMP and promotes secretion of fluids into the cyst lumen via the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. Clinically, tolvaptan causes the picture of renal diabetes insipidus with polyuria due to loss of free water. In a large randomized trial in adults (TEMPO 3:4), tolvaptan has been shown to reduce the rate of GFR loss as well as growth of total kidney volume in adults with ADPKD [90, 110] and has consequently become the first licensed drug for delaying disease progression, but only for adults with rapidly progressive disease. Difficulties of treatment include aquaretic side effects such as large polyuria, thirst and nocturia, which were experienced by over 65% of patients and led 7% to discontinue the drug [111]. Idiosyncratic liver damage is another issue, affecting about 1.2% of patients in TEMPO 3:4 and 3.7% in the extension study TEMPO 4:4. It appears to be a specific but reversible side effect in ADPKD which warrants regular control of liver function enzymes [112]. Another important unresolved question, which is particularly relevant to patients with early ADPKD, is whether the effect of tolvaptan really is sustained in the long-term. While it was continuous over the 3-year period of TEMPO 3:4, the follow-up study up to 5 years was not totally conclusive on this [113–115].

From TEMPO 3:4, there is reason to believe that young patients benefit from tolvaptan too. Two post-hoc analyses in the subgroups of patients with CKD Stage 1 and in 18–24 year olds showed significantly slower growth of kidney volume with treatment compared to placebo [116, 117]. However,
decrease of GFR decline was not significant in both. Patients with CKD 1 and 2 had less hypernatremia than those with CKD 3, and were not more likely to suffer liver damage [116]. Patients with CKD stage 1 had the highest rates of polyuria or study withdrawal due to adverse events [111, 116]. Results of the ongoing first pediatric study of tolvaptan in adolescents are therefore eagerly awaited and can be expected soon [118] (ClinicalTrials.gov identifier: NCT02964273). However, as an initial study, the primary endpoints have been defined as urine osmolality changes and change in kidney volume is only a secondary endpoint. Further study will also be required to define which children are likely to experience rapid progression and would therefore benefit from treatment. The difficulty of this task is illustrated by that fact that for adults with ADPKD different definitions/recommendations across the US, Europe, and Japan result in widely varying groups of eligible patients [119].

A case report has documented the use of tolvaptan in a neonate with severe, recessive-like ADPKD, edema, hyponatremia, and compression of the inferior vena cava [120] with successful resolution of edema and hyponatremia and lack of further kidney growth without significant side-effects over 17 months.

Seeing as tolvaptan therapy is unlikely to be tolerated lifelong and treatments with fewer side-effects would be preferable, it is promising that there are currently 5–10 other ongoing interventional clinical studies for drugs as diverse as mTOR-inhibitors, tyrosine kinase inhibitors, proglitazone, venglustat (oral glucosyl-ceramide synthase inhibitor), lixivaptan (non-peptide vasopressin 2 receptor antagonist) as well as prescribed water intake and caloric restriction diet [121]. Previous experience with drugs which appeared promising, such as mTOR inhibitors and somatostatin analogues, but were not found to preserve kidney function in humans (despite effects on kidney growth and liver cysts respectively [51, 52]) cautions against too much enthusiasm, but there is hope that further treatments will become available in due course.

Non-pharmacological management

Higher salt intake is prospectively associated with worse kidney outcomes in the general population [122], as well as with higher kidney volume and growth in ADPKD [123, 124]. A recent study could also demonstrate a negative effect of salt intake on prospective GFR decline in adults with ADPKD with a wide range of eGFR [125], while in patients with advanced ADPKD it has been shown to increase the risk for a composite renal endpoint including death [124]. While in the general CKD population the negative effects of sodium intake are probably mediated via increased blood pressure and activation of the renin-angiotensin system, in ADPKD sodium-induced increase of vasopressin is a likely additional mechanism leading to cyst growth [125]. Unfortunately, there is a lack of prospective interventional trials [126], but counselling patients with ADPKD to adhere to recommendations on salt intake appears wise, as especially younger patients often have much higher salt intake than recommended for the general population [125].

Similarly, deliberate high water intake can suppress endogenous vasopressin (and its surrogate marker copeptin) and can be assumed to be beneficial because the efficacy of tolvaptan therapy correlates with copeptin levels [51]. However, a small interventional trial suggests the opposite clinical effect [127], so results of an ongoing larger randomized trial are eagerly awaited [128]. Others have shown that a low osmolar diet (low sodium, low protein and adjusted water intake) can decrease copeptin in adults with ADPKD [129], but protein intake itself did not correlate with GFR decline in ADPKD [125]. Also, protein restriction has potential side effects in growing children and could not be shown to slow GFR decline in a pediatric group of mixed-cause CKD [130]; therefore, low osmolar diet and protein restriction should not be recommended for children with ADPKD.

In addition to counseling families on lifestyle factors that affect cardiovascular risk, such as exercise and avoiding obesity and smoking, it is useful to point out patient organizations, which exist both internationally and in several countries. The interactive self-management tool “ADPKD Patient route map” [131, 132] is based on a multidisciplinary position statement and available in several languages.

**Perspectives for pediatric ADPKD research**

The host of adult trials investigating interventions to delay progression of ADPKD has brought exciting perspectives for pediatric patients too. However, prior to the use of disease modifying drugs in children with ADPKD, it is necessary to establish reliable prediction models for estimating lifetime risk of kidney failure applicable to this population. The long delay between childhood and average age of kidney failure makes this a difficult task. While some factors can probably be inferred from adults, such as genotype (truncating vs. non-truncating PKD1, PKD1 vs. PKD2), early onset of hypertension or urological events [50], these have not been validated in children, and probably need to be refined further. For example, radiological features need adjustment as enlargement of total kidney volume is uncommon in pediatric ADPKD, MRI is more difficult in children who need sedation, but ultrasound is feasible more often because of smaller kidneys. Several studies have already identified a link between larger kidneys and higher blood pressure in children with ADPKD [15, 17, 23, 133]. However, a predictive effect has been examined only for blood pressure on increase of kidney volume [23, 133], but not vice versa. Also, further knowledge on the course of glomerular hyperfiltration and genetic modifiers may be
especially relevant to predicting disease progression for those who have not yet suffered clinical events or loss of kidney function. It is hoped that a new international registry for children with ADPKD (ADPedKD, www.adpedkd.org) will pave the way to larger-scale longitudinal follow-up studies and improve our understanding about the most informative predictive factors for clinical outcomes in children [134].

In parallel, the ongoing trial on the effect of tolvaptan in children is an important step forward to studying disease modifying agents for pediatric ADPKD. However, less industry-driven research into the effects of statins in children and non-pharmacological interventions such as low-salt and high-water intake is also needed. If further agents are effective in adults, their pediatric use will have to be considered.

**Conclusion**

Progress on understanding disease manifestations of ADPKD in childhood means that children with an affected parent should no longer be ignored in the medical management and be regularly screened for hypertension and proteinuria. Pediatric nephrologists can help to spread this wind of change by raising awareness among the wider medical community and affected families, who are often pre-occupied with more severe disease manifestations in older relatives. Considering the high prevalence of cardiovascular morbidity in adults with ADPKD, which often precedes loss of kidney function, opportunities for early control of hypertension and establishing healthy lifestyle habits should not be missed. Diagnostic testing of at-risk children in families with classical ADPKD should not be rushed into, but repeated counselling about issues involved can enable a process of shared decision-making between the child, parents and physicians.

Pharmaceutical treatments to delay progression of ADPKD provide hopeful prospects for patients. However, before tolvaptan or other drugs can be used in children with ADPKD, valid prediction models are urgently needed to select appropriate patient populations and the long-term safety and sustained effect need to be verified.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** The authors declare that they have no conflict of interest. C.G. is supported by the German Federal Ministry of Research and Education (BMBF grant 01GM1903I). C.B. holds a part-time faculty appointment at the University of Freiburg in addition to his employment with the Limbach Group for which he heads and manages Limbach Genetics. His research lab receives support from the Deutsche Forschungsgemeinschaft (DFG) (BE 3910/8-1 and BE 3910/9-1, and Collaborative Research Center SFB 1453) and the Federal Ministry of Education and Research (BMBF, 01GM19031 and 01GM1903G). D.M. is supported by the Research Foundation Flanders (FWO) (G0C8290N) and UZ Leuven (Belgium). D.M. (representing her institution KU Leuven) reports research grants and/or participation in advisory boards for Otsuka, Galapagos and Genzyme, all outside the submitted work.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Reed BY, McFann K, Bekheirnia MR, Nobkhithaghighi N, Masoumi A, Johnson AM, Shamshiraz AA, Kelleher CL, Schrier RW (2008) Variation in Age at ESRD in Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis 51:173–183. https://doi.org/10.1053/j.ajkd.2007.10.037
2. Fick GM, Duley JT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA (1994) The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4:1654–1660
3. Mekahli D, Woolf AS, Bockenhauer D (2010) Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:2275–2282. https://doi.org/10.1007/s00103-010-1617-8
4. Helal I, Reed B, McFann K, Yan X-D, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW (2011) Glomerular Hyperfiltration and Renal Progression in Children with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 6:2439–2443. https://doi.org/10.2215/CJN.01010211
5. Krause L, Sarganas G, Thamm R, Neuhauer H (2019) Headache, abdominal and back pain in children and adolescents in Germany: Results from KIGGS Wave 2 and trends. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 62:1184–1194. https://doi.org/10.1007/s00467-019-01007-8
6. Zittema D, Boertien WE, van Beek AP, Dullaart RPF, Franssen CFM, de Jong PE, Meijer E, Gansevoort RT (2012) Vasopressin, Copeptin, and Renal Concentrating Capacity in Patients with Autosomal Dominant Polycystic Kidney Disease without Renal Impairment. Clin J Am Soc Nephrol 7:906–913. https://doi.org/10.2215/CJN.11311111
7. Boyer O, Gagnadoux M-F, Guest G, Biebuyck N, Charbit M, Salomon R, Niaudet P (2007) Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth. Pediatr Nephrol 22:380–388. https://doi.org/10.1007/s00467-006-0327-8
8. Fenel F, Janda J, Bláhová K, Hřibal Z, Štekrlová J, Puchmajerová A, Seeman T (2009) Genotype–phenotype correlation in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 24:983–989. https://doi.org/10.1007/s00467-008-1090-9
9. Shamshiraz A, Bekheirnia RM, Kamgar M, Johnson AM, McFann K, Cadnapaphornchai M, Haghhighi NN, Schrier RW (2005) Autosomal-dominant polycystic kidney disease in infancy and childhood: Progression and outcome. Kidney Int 68:2218–2224. https://doi.org/10.1111/j.1523-1755.2005.00678.x
10. Tee JB, Acott PD, McLellan DH, Crocker JFS (2004) Phenotypic heterogeneity in pediatric autosomal dominant polycystic kidney
11. Gabow PA, Duley I, Johnson AM (1992) Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 10:140–143
12. Marlais M, Cuthell O, Langan D, Dudley J, Sinha MD, Winyard PJD (2016) Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. Arch Dis Child 101:1142–1147. https://doi.org/10.1136/archdischild-2015-310221
13. Lai S, Mastroluca D, Matino S, Panebianco V, Vitarelli A, Capotosto L, Turinese I, Marinelli P, Rossetti M, Galani A, Baiocchi P, D’Angelo AR, Palange P (2017) Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease. Kidney Blood Press Res 42:1290–1302. https://doi.org/10.1159/000486011
14. Kelleher CL, McFann KK, Johnson AM, Schrier RW (2004) Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 17:1029–1034. https://doi.org/10.1016/j.amjhy.2004.06.020
15. Seeman T, Dusek J, Vondrichová H, Kyncl M, John U, Misselwitz J, Janda J (2003) Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8:107–110. https://doi.org/10.1097/1.bbp.0000085762.28312.4a
16. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective Change in Renal Volume and Function in Children with ADPKD. Clin J Am Soc Nephrol 4:820–829. https://doi.org/10.2215/CJN.02810608
17. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192–1196. https://doi.org/10.1038/ki.2008.397
18. Marlais M, Rajalingam S, Gu H, Savis A, Sinha MD, Winyard PJ (2019) Central blood pressure and measures of early vascular disease in children with ADPKD. Pediatr Nephrol 34:1791–1797. https://doi.org/10.1007/s00467-019-04267-7
19. Karava V, Benzoud C, Hogan J, Dossier C, Denjean AP, Deschênes G (2018) Early cardiovascular manifestations in children and adolescents with autosomal dominant polycystic kidney disease: a single center study. Pediatr Nephrol 33:1513–1521. https://doi.org/10.1007/s00467-018-3964-9
20. Ecler T (2013) Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 9:2–11. https://doi.org/10.2174/1573420111309010002
21. Chapman AB, Stepiakowski K, Rahbari-Oskoui F (2010) Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17:153–163. https://doi.org/10.1053/j.ackd.2010.01.001
22. Gansevoort RT, Meijer A, Van der Gaag E, Van der Meer F, Van der Graaf Y, De Keizer F, et al. (2006) Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3·4 Trial. Nephrol Dial Transplant 21:1409–1414. https://doi.org/10.1093/ndt/gfl022
23. Fick-Brosnaham GM, Tran ZV, Johnson AM, Strain JD, Gabow PA (2001) Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59:1654–1662. https://doi.org/10.1046/j.1523-1755.2001.095001564.x
24. Sharp C, Johnson A, Gabow P (1998) Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 9:1908–1914
25. Selistre L, de Souza V, Ranchin B, Hadj-Aissa A, Cochot P, Dubourg L (2012) Early renal abnormalities in children with post-natally diagnosed autosomal dominant polycystic kidney disease. Pediatr Nephrol 27:1589–1593. https://doi.org/10.1007/s00467-012-2192-y
26. Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B (2016) Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 44:171–178. https://doi.org/10.1159/000448695
27. Jo WR, Kim SH, Kim KW, Suh CH, Kim JK, Kim H, Lee JS, Oh WY, Choi SE, Pyo J (2017) Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: A systematic review and meta-analysis. Eur J Radiol 95:56–65. https://doi.org/10.1016/j.ejrad.2017.07.023
28. Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Primers 4:50. https://doi.org/10.1038/s41571-018-0047-y
29. Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA (1995) Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2032–2036
30. Bergmann C (2019) Early and Severe Polycystic Kidney Disease and Related Ciliopathies: An Emerging Field of Interest. Nephron 141:50–60. https://doi.org/10.1159/000493532
31. Faguer S, Chassaing N, Bandin F, Prouheze C, Garnier A, Casemanyou A, Huard A, Schanstra JP, Calvas P, Decramer S, Chauveau D (2014) The HNF1B score is a simple tool to select patients for HNF1B gene analysis. Kidney Int 86:1007–1015. https://doi.org/10.1038/ki.2014.202
32. Bergmann C (2015) ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr Nephrol 30:15–30. https://doi.org/10.1007/s00467-013-2706-2
33. Seeman T, Fořtová M, Sopko B, Průša R, Pohl M, John U (2019) Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease. Ann Clin Biochem 56:90–94. https://doi.org/10.1177/0004563218785190
34. Su X, Driscoll K, Yao G, Raed A, Wu M, Beales PL, Zhou J (2014) Bardet-Biedl syndrome proteins 1 and 3 regulate the ciliary trafficking of polycystic kidney disease 1 protein. Hum Mol Genet 23:5441–5451. https://doi.org/10.1093/hmg/ddu267
35. Zerres K, Rudnik-Schöneborn S, Deget F (1993) Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft für Pädiatrische Nephrologie). J Med Genet 30:583–588. https://doi.org/10.1136/jmg.30.7.583
36. Aãdrãtãz ét M-P, Corbiere C, Lebba S, Morinvière V, Broux F, Louillet F, Fischbach M, Zaloszyc A, Cloarec S, Meteau E, Baudouin V, Deschênes G, Zerres K, van Dijk B, van der Veen L, Karsen B, Prins D, et al. (2018) Bardet-Biedl syndrome in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft für Pädiatrische Nephrologie). J Med Genet 30:583–588. https://doi.org/10.1136/jmg.30.7.583
81. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Manica G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wühl E, Zanchetti A (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887–1920. https://doi.org/10.1097/JHJ.0000000000001039

82. (2012) Chapter 6: Blood pressure management in children with CKD ND. Kidney Int Suppl 2:372–376. https://doi.org/10.1038/kinsup.2012.56

83. Dionne JM, Harris KC, Benoit G, Feber J, Poirier L, Cloutier L, Nakhlia M, Rabi DM, Daskalopoulou SS, Fournier A (2017) Hypertension Canada’s 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. Can J Cardiol 33:577–585. https://doi.org/10.1016/cjca.2017.03.007

84. Chiang Y-W, Yu T-M, Huang S-T, Sun K-T, Lo Y-C, Fu P-K, Lee B-J, Chen C-H, Lin C-L, Kao C-H (2018) Young-Adult Polycystic Kidney Disease is Associated with Major Cardiovascular Complications. Int J Environ Res Public Health 15:903. https://doi.org/10.3390/ijerph15040903

85. de Chickera S, Akbary A, Levin A, Tang M, Brown P, Djurdjev O, Biyani M, Clark EG, Sood MM (2018) The Risk of Adverse Events in Patients With Polycystic Kidney Disease With Advanced Chronic Kidney Disease. Can J Kidney Health Dis 5: 20543581118774537. https://doi.org/10.1177/20543581118774537

86. Chen H, Watnick T, Hong SN, Daly B, Li Y, Seliger SL (2019) Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients. BMC Nephrol 20:386. https://doi.org/10.1186/s12882-019-1555-z

87. Schrier RW, McFann K, Johnson A, Chapman A, Edelstein C, Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GFM (2015) Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev:CD010294. https://doi.org/10.1002/14651858.CD010294.pub2

88. ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurovska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudad P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen A-M, Sallay P, Jcek N, Berg U, Caliskan S, Wygoda S, Hobbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehsil O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650. https://doi.org/10.1056/NEJMoa0902066

89. Ederer T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW (2001) Diuretics versus Angiotensin-Converting Enzyme Inhibitors in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 21:98–103. https://doi.org/10.1159/000046231

90. Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoa K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP (2008) Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy+/+ rat. Kidney Int 73:269–277. https://doi.org/10.1038/sj.ki.5002629

91. Ederer T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW (2000) Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 35:427–432

92. Nuthahara K, Higashihara E, Horiie S, Kamura K, Tsuchiya K, Yamamoto I, Higaki Y, Shimizu T (2005) Calcium Channel Blocker Versus Angiotensin II Receptor Blocker in Autosomal Dominant Polycystic Kidney Disease. Nephron Clin Pract 99:c18

93. Steinman TI, Winklhofer FT, Brosnahan G, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Schaefer F, McQuade RD, Blais JD, Czerwiec FS, Westen GJPV, Price LS, Hoen PAC 't, Peters DJM (2020) Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles. EBioMedicine 51:102585. https://doi.org/10.1016/j.ebiom.2019.11.046

94. Grantham JJ (2015) Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol 30:1053–1062. https://doi.org/10.1007/s00467-014-2882-8

95. Bennett H, McEwan P, Hamilton K, O'Reilly K (2019) Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrol 20:136. https://doi.org/10.1186/s12882-019-1290-5

96. Walz G, Budke K, Mannaa M, Nünberg J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörli WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Bächert M, May C, Gschaidmeier H, Kramer S, Eckardt K-U (2010) Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 363:830–840. https://doi.org/10.1056/NEJMoa1003491

97. Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889–896. https://doi.org/10.2215/CJN.08350813
104. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF (2014) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev CD007784. https://doi.org/10.1002/14651858.CD007784.pub2

105. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ (2001) Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16: 2152–2157. https://doi.org/10.1093/ndt/16.11.2152

106. Fassett RG, Coombe JS, Packham D, Fairley KF, Kincaid-Smith P (2010) Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol 44:56–61. https://doi.org/10.3109/00365590903359908

107. Brosnahan G, Abebe KZ, Rahbari-Oskoui FF, Patteson CG, Bae KT, Schier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE, The Halt Pkd Investigators (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Curr Hypertens Rev. https://doi.org/10.2174/1573402113666170427142815

108. Carreau V, Girardet J-P, Bruckert E (2011) Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Paediatric Drugs 13:267–275. https://doi.org/10.3109/13896403.2010.542632

109. Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D (2020) A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials. Clin J Am Soc Nephrol 15:643–650. https://doi.org/10.2215/CJN.08170719

110. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Hiigashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 367:2407–2418. https://doi.org/10.1056/NEJMoa1205511

111. Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD (2017) Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. Kidney Int Rep 2:1132–1140. https://doi.org/10.1016/j.ekir.2017.07.004

112. Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA (2015) Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf 38:1103–1113. https://doi.org/10.1007/s40264-015-0327-3

113. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33: 477–489. https://doi.org/10.1093/ndt/gfx043

114. Gross P, Schirurschke H, Paliege A (2019) Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers? Nephrol Dial Transplant 34:35–37. https://doi.org/10.1093/ndt/gfy298

115. Anderson CL (2020) Doubts about the efficacy of tolvaptan for polycystic kidney disease. Clin Nephrol 93:307–309. https://doi.org/10.5414/CN109927Letter

116. Torres VE, Hiigashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS (2016) Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol 11:803–811. https://doi.org/10.2215/CJN.06300615

117. Raina R, Chakraborty R, DeCoy ME, Kline T (2020) Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatr Res. https://doi.org/10.1038/s41390-020-0942-2

118. Schaefer F, Mehaki D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphomchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE (2019) Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr 178:1013–1021. https://doi.org/10.1007/s00431-019-03384-x

119. Wulfmeyer VC, Auber B, Haller H, Schmitt R (2019) Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients. Am J Nephrol 50:281–290. https://doi.org/10.1159/000502634

120. Gilbert RD, Evans H, Olalekan K, Nagra A, Haq MR, Griffiths M (2017) Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatr Nephrol 32:893–896. https://doi.org/10.1007/s00467-017-3584-9

121. Testa F, Magistroni R (2020) ADPKD current management and ongoing trials. J Nephrol 33:223–237. https://doi.org/10.1007/s40620-019-00679-y

122. Smyth M, Griffin M, Yusuf S, Mann JFE, Reddan D, Canavan M, Newell J, O’Donnell M (2016) Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. J Ren Nutr 26:288–298. https://doi.org/10.1007/j.2016.01016

123. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) (2011) Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:640–647. https://doi.org/10.2215/CJN.03250410

124. Torres VE, Abebe KZ, Schier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91: 493–500. https://doi.org/10.1016/j.kint.2016.10.018

125. Kramers BJ, Koorevaar IW, Drenth JPH, de Fijter JW, Neto AG, Wetzels JF, Zietse R, Gansevoort RT, Meijer P (2020) Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney Int. https://doi.org/10.1016/j.kint.2020.04.053

126. McMahon EJ, Campbell KL, Bauer JD, Mudge DW (2015) Effects of simvastatin on renal function in autosomal dominant polycystic kidney disease. A secondary analysis of the TEMPO 4:4 trial. Nephrol Dial Transplant 30:3547–3555. https://doi.org/10.1093/ndt/gfv034

127. Peters DJ, Vart P, Wetzels JF, Zietse R, Gansevoort RT, Meijer P (2015) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. J Renal Nutr 26:288–298. https://doi.org/10.1007/s40620-019-00679-y

128. Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernandez M, Foster S, Halseo I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vliayuri E, Rangan GK (2018) Randomised controlled trial to
determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8:e018794. https://doi.org/10.1136/bmjopen-2017-018794

129. Amro OW, Paulus JK, Noubary F, Perrone RD (2016) Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial. Am J Kidney Dis 68:882–891. https://doi.org/10.1053/j.ajkd.2016.07.023

130. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 349:1117–1123

131. Harris T, Sandford R, de Coninck B, Devuyst O, Drenth JPH, Ecder T, Kent A, Gansevoort RT, Göröz JL, Ong ACM, Pirson Y, Torres VE, Budde K, Clément D, Derchi LE, Eleftheroudi M, Levchenko E, Peters D, Van Poppel H, Vanholder R (2018) European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. European ADPKD Forum and Multispecialist Roundtable participants. Nephrol Dial Transplant 33:563–573. https://doi.org/10.1093/ndt/gfx327

132. ADPKD Patient Route Map. PKD International. https://pkdinternational.org/adpkd-route-map. Accessed 23 Oct 2020

133. Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369–376. https://doi.org/10.2215/CJN.03780410

134. De Rechter S, Bockenhauer D, Guay-Woodford LM, Liu I, Mallett AJ, Soliman NA, Sylvestre LC, Schaefer F, Liebau MC, Mekahli D, ADPedKD Consortium (2019) ADPedKD: A Global Online Platform on the Management of Children With ADPKD. Kidney Int Rep 4:1271–1284. https://doi.org/10.1016/j.ekir.2019.05.015

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.